Multifocal Inflammatory Pseudotumor of the Temporal Bone, Maxillary Sinus, and Orbit. Issue 10 (December 2018)

• Record Type: Journal Article
• Authors: Sakano, Hitomi; Shih, Cheng-Ping; Jafari, Aria; DeConde, Adam; Harris, Jeffrey P.
• Is Part Of: Otology & neurotology. Volume 39:Issue 10(2018)
• Publication Date: 2018-12
• Subjects: Fibrous xanthoma -- Histiocytoma complex -- Inflammatory myofibroblastic tumor -- Inflammatory myofibrohistiocytic proliferation -- Inflammatory pseudotumor -- Plasma cell granuloma -- Rituximab -- Xanthomatous pseudotumor; Otology -- Periodicals; Ear -- Diseases -- Periodicals; Skull base -- Surgery -- Periodicals; 617.8005
• DOI: 10.1097/MAO.0000000000001968
• Languages: English
• ISSNs: 1531-7129

Abstract

Abstract : Objective: This is the first report of multifocal inflammatory pseudotumor (IPT) involving the temporal bone, orbit and paranasal sinus, and the use of rituximab as adjunctive therapy in multifocal temporal bone IPT. Patient: We describe a 46-year-old man with orbital and maxillary sinus IPT, whose disease progressed despite radiation and steroid burst. He then developed contralateral mastoid disease, otalgia, aural fullness, and hearing loss. Intervention: He was initiated on rituximab and prednisone therapy. Mastoidectomy with near-total tumor removal was accomplished and histopathology confirmed IPT. A literature review was also performed. Main Outcome Measure: Tumor regression or recurrence. Result: Despite disease progression after radiation and steroids, his orbital, sinus, and mastoid disease improved after surgery, steroids, and rituximab. A review of four other previously reported cases of multifocal disease involving the temporal bone suggest that multifocal disease may be a more aggressive entity with higher recurrence rate compared with solitary disease. Although surgery and steroids are typically recommended, there is currently no consensus treatment recommendation. Conclusions: Multifocal IPT of the temporal bone is a rare but aggressive entity for which surgery and steroid combination therapy should be first line treatment. We suggest rituximab may be an effective adjunctive treatment particularly for recurrent disease or where systemic therapy may be favored.